Navigation Links
Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
Date:11/9/2012

PRINCETON, N.J., Nov. 9, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced that Chief Medical Officer, Dr. Michael H. Davidson, recently presented data from the Company's Phase 3 EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial at the Scientific Sessions of the American Heart Association (AHA) in Los Angeles, CA. Dr. Davidson's presentation specifically focused on the effects of Epanova, Omthera's lead, Omega-3 free fatty acid compound for the treatment of patients with hypertriglyceridemia (very high triglycerides), on apolipoprotein C-III (ApoC-III), one of the tertiary endpoints of the EVOLVE study.  Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ApoC-III, a protein component of very low density lipoprotein (VLDL), is an independent predictor of recurrent coronary events and is found to be elevated in patients suffering from very high triglycerides.  

ApoC-III inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich lipoproteins, thereby reducing the conversion of VLDL to LDL and enhancing the formation of more atherogenic small, dense LDL.   Various clinical trials indicate that elevated levels of ApoC-III are an independent risk predictor for coronary heart disease. Lower levels of ApoC-III are associated with lower rates of coronary heart disease, making ApoC-III an important and novel therapeutic target. 

Omthera's EVOLVE trial evaluated 399 patients in four dosing groups: Epanova 2g/day, Epanova 3g/day, Epanova 4g/day and control (olive oil 4g/day).  An analysis of these patients showed statistically significant reductions in ApoC-III of 11% (p=0.022) in the 2g cohort and 14% (p<0.001) in the 4g cohort, compared to olive oil (2%).  

The analysis also showed statistically significant reductions in TG of 26% (p=0.003) in the 2g cohort and 31% (p<0.001) among patients in the 4g cohort, compared to 4% for olive oil. There was also statistically significant reduction in Non-HDL-C in all dose groups, with decreases in Non-HDL-C of approximately 8% (p<0.05) in the 2g cohort and 10% (p<0.01) in the 4g cohort. Non-HDL-C is widely viewed as the most accurate predictor of cardiovascular disease.  Reductions in ApoC-III were associated with the expected increase in HDL-C with an increase conversion of VLDL to LDL leading to an increase in LDL-C.  There was also an increase in LDL particle size.  Independent studies suggest that Omega-3 fatty acid formulations containing DHA alone, decrease TG and VLDL-C levels and increase LDL-C levels in patients with severe hypertriglyceridemia and that those containing EPA alone, lower triglycerides (TG) to a similar extent as EPA and DHA, but also fail to lower ApoC-III.  

Commenting on these results, Dr. Davidson noted, "ApoC-III represents a key link between hypertriglyceridemia and the probability of coronary events. We are therefore highly encouraged by the data from this analysis of the EVOLVE trial, which shows the unique effects of Omega-3 products containing both EPA+DHA, like Epanova, on this important marker of cardiovascular risk. These findings highlight the importance of incorporating both EPA and DHA in patient therapy to provide comprehensive risk management for those with hypertriglyceridemia." 

About Epanova™
Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera has developed a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega‐3 products currently available. Triglyceride, as well as Non-HDL-C lowering with Epanova was recently observed in the Company's 1,000 patient, global Phase 3 program, consisting of its EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) and ESPRIT (Epanova combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol) clinical trials.  In all studies performed to date, Epanova has also demonstrated a very good safety and tolerability profile.

About Hypertriglyceridemia
Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with approximately 40 million of those diagnosed with hypertriglyceridemia (triglycerides greater than 200mg/dL) and an estimated 4 million with very high triglyceride levels (triglycerides greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.

About Omthera Pharmaceuticals, Inc.
Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, specialty pharmaceutical company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit www.omthera.com

Contact:
Christian Schade
Chief Financial Officer
Omthera Pharmaceuticals
908-741-6402
CSchade@Omthera.com


'/>"/>
SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
4. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
7. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
8. Genoa Pharmaceuticals announces $1.2M Financing
9. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
10. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
11. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):